Published in final edited form as:

Semin Cancer Biol. 2008 June ; 18(3): 199–210.

Endogenous Morphine/Nitric Oxide-Coupled Regulation of Cellular Physiology and Gene Expression: Implications for Cancer Biology

George B. Stefano^{a,*}, Richard M. Kream^a, Kirk J. Mantione^a, Melinda Sheehan^a, Patrick Cadet^a, Wei Zhu^a, Thomas V. Bilfinger^b, and Tobias Esch^c

^a Neuroscience Research Institute, State University of New York - College at Old Westbury, P.O. Box 210, Old Westbury, NY 11568, USA

^b Department of Surgery, State University of New York at Stony Brook, HSC T19 Rm 80, Stony Brook, NY 11794, USA

^c Division of Integrative Health Promotion, Coburg University of Applied Sciences, Postfach 1652, Coburg 96406, Germany

Abstract

Cancer is a simplistic, yet complicated, process that promotes uncontrolled growth. In this regard, this unconstrained proliferation may represent primitive phenomena whereby cellular regulation is suspended or compromised. Given the new empirical evidence for a morphinergic presence and its profound modulatory actions on several cellular processes it is not an overstatement to hypothesize that morphine may represent a key chemical messenger in the process of modulating proliferation of diverse cells. This has been recently demonstrated by the finding of a novel opiate-alkaloid selective receptor subtype in human multilineage progenitor cells (MLPC). Adding to the significance of morphinergic signaling are the findings of its presence in plant, invertebrate and vertebrate cells, which also have been shown to synthesize this messenger as well. Interestingly, we and others have shown that some cancerous tissues contain morphine. Furthermore, in medullary histolytic reticulosis, which is exemplified by cells having hyperactivity, the μ_3 (μ_3) opiate select receptor was not present. Thus, it would appear that morphinergic signaling has inserted itself in many processes taking a long time to evolve, including those regulating the proliferation of cells across diverse phyla.

Keywords

endogenous morphine; μ_3 opiate receptor; nitric oxide; stem cell; cancer

* Corresponding Author: Dr. George B. Stefano, Neuroscience Research Institute, SUNY College at Old Westbury, P.O. Box 210, Old Westbury, NY 11568, USA Tel: 001-516-876-2732; Fax: 001-516-876-2727; Email: gstefano@sunynri.org.

Email addresses: gstefano@sunynri.org (GB Stefano); rmkream@sunynri.org (RM Kream); kmantione@sunynri.org (KJ Mantione); msheehan@sunynri.org (M Sheehan); patcad@sunynri.org (P Cadet); zhuwei@sunynri.org (W Zhu); tbilfinger@notes.cc.sunysb.edu (TV Bilfinger); esch@fh-coburg.de (T Esch)

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Historical Context and Clinical Implications

Morphine and chemically related opiate alkaloids represent time-tested analgesic principles for management of severe pain associated with metastatic disease [1,2]. A substantial body of accumulated evidence, however, documents a cadre of cellular/physiological effects associated with pharmacological administration of morphine and related opiate alkaloids that lie outside the realm of anti-nociception and appear to be mediated by indirect and/or “non-traditional” mechanisms. Notably, complementary studies have monitored the inhibitory effects of morphine treatment on tumor growth in human patient populations and in selected animal models. These key observations require re-examination and re-interpretation in light of recent empirical evidence supporting the *de novo* expression of chemically authentic morphine by animal cells [3,4].

Because animal cells and complex organ systems have the ability to carry out *de novo* synthesis of morphine via highly regulated enzyme-linked catalytic steps (Figure 1) [3,4], the clinical relevance of physiological and/or pharmacological perturbations of ongoing morphinergic cellular signaling pathways to cancer biology becomes compellingly evident [5-8].

Accordingly, the present review will develop a brief schematic in support of morphine's essential role as an autocrine/paracrine regulatory factor devoted to hierarchal integration of cellular function [9,10] via intimate association with a novel μ_3 opioid receptor subtype functionally coupled to stimulated production and release of the primordial signaling molecule nitric oxide (NO) (Figure 2). Several newly formulated hypotheses are proposed to explain the anti-proliferative effects of morphinergic signaling based on recently published empirical evidence combined with re-evaluation of clinical and pre-clinical databases.

Morphine, inhibition of tumor progression, and immune competence

Complementary pre-clinical and clinical studies have monitored inhibitory effects of pharmacologically administered morphine on tumor growth. For example, a pre-clinical murine animal model of tumor progression has demonstrated that repeated administration of morphine results in significantly diminished tumor cell-induced tissue destruction [11]. Pre-clinical observations are complemented by a series of clinical studies demonstrating that both pre- and post-operative administration of analgesic dosages of morphine as an adjuvant to cancer surgery operationally reduces systemic cell dissemination of tumor cells [12-14]. An additional clinical study proposes an indirect analgesic or extra-analgesic mechanism for the observed anti-metastatic effects of administered morphine, potentially involving enhanced host resistance to tumor cells entering the systemic circulation during surgical manipulation [15].

Morphine has been demonstrated to decrease cell growth of human breast cancer cells *in vitro*, despite significant cellular expression of traditional μ_1 receptors [16]. The question was raised whether the anti-proliferative effects of morphine could be mediated through interaction with other receptor systems, particularly, since receptor binding studies revealed that only some tumors express μ receptors [17]. For example, Manneckjee and Minna found that the inhibitory effects of morphine on lung cancer growth could be reversed by nicotine, pointing towards an opioid-acetylcholine interplay on systemic or receptor levels [18]. In another study, it has been shown that morphine may exert its anti-proliferative effects on breast cancer through interaction with the somatostatin receptor SSTR2, suggesting a functional interaction of morphine with the inhibitory somatostatinergic system [19]. This hypothesis is supported by findings that show a direct inhibitory effect of somatostatin analogues on human tumor growth [20-22]. The critical question, however, whether morphine acts via μ receptor binding to exert its potentially anti-proliferative, anti-neoplastic functions, is elucidated by recent findings that suggest other physiologically active μ opioid receptor splice variants to play a critical role, variants that may be present and operational in immune and vascular tissues and that had gone

previously undetected [23,24]. Thus, when examining the underlying molecular mechanisms of morphine down regulation, particularly in cancer, it seems necessary to also look for and consider these receptor variants. In any case, however, it appears that morphine has the potential to be protective in many tissues in response to stress and injuries, including cancer damage [2,10,11]

The complexity of morphine-tumor interaction can also be observed in angiogenesis: morphine may enhance angiogenesis by μ receptor activation, and this mechanism may be protective, e.g., in wound healing, where tissue injury is overcome [25]. However, morphine also potentially induces angiogenesis in cancer, thereby possibly facilitating tumor growth and metastatic potential [26]. In part, this effect may be due to rebound excitation, following morphine's immediate action, which is down regulating in nature [10,27,28]. After morphine-stimulated down regulation, e.g., immune suppression, this rebound excitation may allow cells, i.e., immune system, to restore enhanced surveillance, [29,30]. This capacity clearly would have survival value, and it may be further supported by the fact that this mechanism can already be observed in organisms that evolved 500 million years before man [29].

Pharmacological administration of morphine and related opiate alkaloids has been demonstrated to mediate positive effects on host immunity against proliferation of malignant cells [13,31,32]. For example, temporally dependent morphine treatment enhances human cytotoxic T lymphocyte activity and interferon gamma production *in vitro*, resulting in enhanced T cell-mediated immune responses [32]. Furthermore, it has been suggested that morphine's anti-metastatic effects when preemptively administered prior to cancer surgery involve functional recruitment of large granular lymphocytes and natural killer (NK) cells [13]. The contribution of NK cell activation to the anti-proliferative effects of pharmacologically administered morphine, however, remains a controversial issue and requires further investigation [13,31,32]. The same caveat applies to potential role morphine-dependent enhancements of lymphokine activated killer cell activity [31]. Interestingly, a relatively recent study indicates that the synthetic phenylpiperidine μ_1 receptor opiate agonist fentanyl suppresses NK cell activity, thereby increasing the risk of tumor metastasis [33]. The opposite pharmacological effects of the naturally occurring opiate alkaloid morphine and the synthetic opioid analgesic on NK cell activity linked to *in vivo* tumor progression may be functionally linked to their differential effects on μ_3 receptor activation. As discussed below, morphine and related morphinan opiate alkaloids are highly efficacious activators of the μ_3 receptor, whereas fentanyl and related synthetic opioids are observed to be without effect.

Finally, opioid peptides, in general, appear to have proinflammatory capabilities throughout the body, whereas opiate alkaloids like morphine may represent a class of immune and vascular systems' anti-inflammatory, i.e., inhibitory or down regulating, key players [10,34,35]. Hence, both – opioids and opiates – theoretically present themselves as potential candidates for tumor growth modification.

Apoptotic and transcriptional effects of morphine administration on tumor growth

Researchers recently have proposed a protective role for morphine against tumor growth and metastasis through induction of apoptosis in tumor cells [36,37]. This conclusion also derived from findings related to chronic morphine administration in latent pain situations, where morphine's cytotoxic effects may be partially associated with apoptosis induction [36]. Again, we see the double-edged sword in morphine physiology and regulation, however, the specific mechanisms by which morphine influences tumor growth are far from being fully understood. This fact may also be due to a lack of realization of an endogenous autoregulatory morphine signaling system [51,63,98].

Morphine inhibits tumor necrosis factor (TNF)-alpha mRNA expression and release, which attenuates the *in vitro* growth of various cancer cell lines [38]. Furthermore, TNF-alpha is regulated by the (pro)inflammatory transcription factor nuclear factor kappa B (NFkB) [39, 40], which augments cell proliferation and is regulated, among others, by morphine or its derivatives: Inhibition of NFkB in human cancer cell lines – related to morphine exposure – is associated with higher apoptosis induction [41]. Similarly, it has been shown that an inhibition of NFkB attenuates apoptosis resistance in lymphoid cells [42]. Finally, we demonstrated that morphine can directly inhibit NFkB actions via NO release [43,44] (also see below).

Endogenous Morphine Expression by Animal Cells

Based on the historical belief that morphine was not present endogenously in animals, studies on the pharmacologic properties of morphine and morphine-like substances had focused on the effects of exogenous opiates, a family of important analgesic and anti-nociceptive drugs. This focus changed following the discovery [45] that morphine binds to the same receptors used by endogenous opioid peptides. An important step forward was the demonstration of endogenous opiates in various vertebrate tissues, including the nervous and immune systems [46-48]. At this turning point, a quest began to identify the possible roles played by this new group of endogenous messenger molecules under both physiological and pathological conditions.

Our recent work provides compelling *prima facie* evidence that *de novo* synthesis of chemically authentic morphine is realized by diverse animal cellular systems from L-tyrosine-derived small molecules within a strikingly similar biochemical pathway to that described in opium poppy (Figure 1) [4,81,82,90]. Furthermore, we have monitored a functional linkage of *de novo* morphine synthesis to evoked release of the alkaloid upon physiological demand, suggesting that low steady-state levels of morphine in many, if not all, mammalian organ systems, indicate dynamic utilization and turnover of releasable cellular pools of morphine.

Recent studies from our group employing well established *ex vivo* invertebrate nervous tissue preparations and primary cultures of human white blood cells [3,4,49] and those by Zenk and coworkers using human tumor-derived cell lines [50,51] have markedly facilitated the formulation of an evidence-based model of *de novo* formation of endogenous morphine in animal cells with remarkable similarities to the well-characterized enzymatic pathway described in *Papaver somniferum* [8]. Key observations from these studies indicate that L-tyrosine, its monoamine homolog tyramine, and their respective catechol derivatives, 3,4-dihydroxy-L-phenylalanine (L-DOPA) and dopamine (DA) serve as substrates for *de novo* morphine production and that pharmacological characterization of tyramine utilization as a morphine precursor indicates one or more catalytic steps mediated by microsomal cytochrome P450 2D6 (CYP2D6) [3,4].

The significance of tyramine as a biosynthetic intermediate is validated by *in vitro* enzyme kinetic studies demonstrating dopamine formation via CYP2D6-catalyzed ring hydroxylation of tyramine [52-55] which in turn lends support to the existence of a potentially important tyrosine hydroxylase-independent pool of cytosolic DA that is available for endogenous morphine expression [3,4,49]. These data are complemented by metabolic labeling/isotope enrichment studies employing SH-SY5Y neuroblastoma cells [50,51], indicating asymmetric isotopic labeling of the benzyl and isoquinoline chemical domains of newly formed morphine that is operationally determined by the type of L-tyrosine-derived precursor molecule that is employed: L-tyrosine and L-DOPA are incorporated in both the benzyl and isoquinoline chemical domains of morphine, whereas dopamine and tyramine are only incorporated into the isoquinoline domain.

Taken together, we have formulated a hypothesis, which states that endogenous morphine, used as either a hormone or neurotransmitter down regulates immune, vascular, neural and gut tissues under normal and following trauma situations [10,27,34,56,57]. In this regard, as noted in these reports, tolerance is viewed as a mechanism to ensure that morphine's continued presence does not permanently limit a needed tissue excitatory state, since excitation may be required to overcome a traumatic event, which morphine would continue to down regulate.

Biochemical characterization of a novel opiate-alkaloid selective μ_3 receptor subtype in invertebrate and mammalian tissues

The demonstration of endogenous opiates, i.e., morphine, codeine, in various vertebrate tissues, including the nervous system [14,51,91-95], is quite important for establishing the significance of the μ_3 opiate receptor subtype. There is a body of evidence that shows opiate alkaloids such as morphine, morphine-3- and 6- glucuronide, as well as the morphine putative precursor molecules (thebaine, salutaridine, norcoccinarine, reticuline, tetrahydropapaverine (THP) and codeine) exist in vertebrates [58-61]. In invertebrates, specifically *Mytilus edulis*, the presence of morphine, morphine 6-glucuronide, morphine 3-glucuronide, codeine, THP and reticuline also have been reported [10,48,62-64]. Endogenous opiate levels can be induced to change following stimulation [10]. Morphine has also been found in human plasma [65,66], suggesting a hormonal action with immune, vascular and gut tissues as targets [57,67].

Classical opioid receptors are linked to trimeric G proteins that in turn modulate Ca^{++} and K^+ channels, adenylyl cyclase, and probably other signal transduction systems [68]. In this regard, the μ_3 receptor is also linked to G protein, based on guanine nucleotide effects on agonist binding to the receptor [69]. The μ_3 receptor differed from previously described neuronal opioid receptor subtypes in that it exhibited essentially no or exceedingly low affinity for naturally occurring endogenous opioid peptides or their analogues [70]. However, the opiate alkaloid binding that was present was naloxone sensitive, demonstrating its opiate receptor properties [34]. Also, and of crucial importance, these properties corresponded to effects of opiates, i.e., morphine, on immunocytes that were not mimicked by opioid peptides. In contrast, each of the other opioid receptor subtypes binds at least one of the endogenous opioid peptides with high affinity. Furthermore, certain opiate alkaloids, benzomorphans and other drugs bind to classical opioid receptors but not to the G protein coupled μ_3 receptor [48,69,71-73].

Binding sites for this novel morphine (opiate alkaloid-selective, opioid peptide-insensitive) receptor, designated the μ_3 receptor were first reported to be present in human peripheral blood monocytes and in invertebrate immunocytes and later on other cell types [48,69,71,73-75]. The newly discovered opioid peptides endomorphin-1, -2 and orphanin FQ also do not bind to this opiate receptor subtype [76]. 6-Glucuronide, not the 3-glucuronide metabolite of morphine, binds to the μ_3 receptor. The synthetic phenylpiperidine μ_1 opiate agonist fentanyl does not bind to this receptor as well [69,73,74].

Structural and functional elucidation of a novel opiate-alkaloid selective μ_3 receptor subtype in invertebrate and mammalian tissues

Traditional opioid receptors have been classified as 3 major types, i.e., μ , δ , and κ , and heterogeneous μ , δ , and κ subtypes have also been described [68,77-82]. Historically, amino acid sequences of μ , δ , and κ opioid receptors from several species have been derived from their respective cloned cDNA sequences [83-86].

The μ_3 receptor cDNA, compared with μ_1 , is truncated at the 5'-end, missing several hundred nucleotides, but the middle and conserved region sequences are identical with μ_1 [24]. The 3' end of μ_3 exhibits 100% identity to a portion of the 3' end of the μ_1 variant, followed by a new

fragment of 263 bases, and then a 201-bp fragment of the 3' end of the μ_1 gene untranslated region [24]. As observed presently, the μ_3 opiate receptor represents a typical transmembrane G protein-coupled protein with a novel linkage to constitutive nitric oxide synthase (cNOS) [34,48,69,73,75,87-89]. The novelty and selectivity of this G protein-coupled, naloxone-sensitive receptor was made apparent when a variety of opioid peptides were found to be ineffective in displacing specifically bound 3H-dihydromorphine (DHM) as well as in stimulating NO release, whereas opiate alkaloids were quite potent [24,48]. In this report we found that only one set of μ -specific primers used in the PCR reactions (from map position 896-1336) yielded a specific PCR product [23]. This segment of the cDNA encodes the third extracellular loop of the receptor that is important for μ agonist selectivity [90,91].

To determine if the cDNA clone we isolated was functional and had the biochemical properties expected of the μ_3 receptor, the cDNA was expressed in a heterologous system (Cos-1 cells). Morphine administration to Cos-1 cells transfected with the μ_3 receptor cDNA was observed to effect "real-time" release of NO into the cellular bath medium, as monitored by a NO-selective amperometric nanoprobe [24]. In contrast, morphine administration was observed without effect on NO release from Cos-1 cells transfected with a control cDNA construct. Naloxone antagonized morphine's effect in a dose-dependent manner [24]. The addition of naturally occurring Met- and Leu-enkephalins, as well as the delta opioid receptor peptide agonist DPDPE, did not stimulate NO release in the controls or transfected cells [24]. These results show that transfection of the novel cDNA clone isolated from human testes conferred the expected opiate alkaloid selective and opioid peptide insensitive characteristics of the μ_3 opiate receptor [10,23,70,92]. In addition, we analyzed human heart endothelial tissue, human leukocytes, and Cos-1 transfected cells for expression of the μ_3 receptor-encoding mRNA by Northern blot analysis [24]. A band of the expected size of approximately 1.45 kb was observed in the various tissues [24]. The selectivity of the μ_3 opiate receptor subtype, therefore, provides further evidence for the status of morphine as an endogenous signaling molecule [10].

Demonstration of functionally coupled μ_3 receptor/nitric oxide (NO) cellular signaling in invertebrate and mammalian tissues

There has been in the literature an association of NO with morphine actions. Peripheral morphine analgesia involves NO-stimulated increases in intracellular cGMP [93]. Nitric oxide has been associated with anti-nociception [94] as well as tolerance and dependence [95]. In addition, the morphine-induced suppression of splenic lymphocyte proliferation has been shown to involve enhanced NO expression [96]. Morphine and NO have been functionally linked in the regulation of physiological processes in the gastrointestinal system [57,97]. Furthermore, morphine, not opioid peptides, stimulate constitutive NO release in macrophages, granulocytes, various types of human and rat endothelial cells, invertebrate neurons and immunocytes and in rat median eminence fragments, all in a naloxone antagonizable manner [28,34,76,98-104]. These data suggest that the μ_3 receptor is functionally coupled to stimulated NO production and release in these cells via Ca^{++} stimulated activation of cNOS. Furthermore, morphine's actions in these diverse tissues complement what is known about NO mediating immune and vascular functions, namely that it can down regulate them from an excitatory state or prevent the excitatory state from occurring [27,28,34,104]. These reports NO is also involved in cell growth and maturation, thus implicating morphine as well [5,6,105]. Additional information on opiate alkaloid signaling substances can be summarized as follows: Injection of vertebrate animals with morphine results in deficient macrophage function [106] and an alteration of T-cell activity [107]. Morphine also antagonizes interleukin-1 α or tumor necrosis factor- α -induced chemotaxis in human granulocytes and monocytes [108,109].

Demonstration of biologically relevant morphine/NO-coupled cellular signaling in cancer cells

NO, when released through cNOS pathways, has anti-inflammatory, anti-proliferative capacities [110,111]. However, the specific mechanisms by which increases in NOS activity and the subsequent production of NO may actually cause cytostasis are not clear. This effect, in parts, may be due to the NO-associated inhibition of NFkB [40,111]. NO stabilizes the NFkB inhibitor, i.e., inhibitory kappa B alpha (IkBa), and this increased NFkB inhibition, as well as the correlated decrease of NFkB binding to the DNA, may attenuate apoptosis resistance in cancer cells (as described), possibly leading to down regulation of tumor growth [10,43,44, 112,113]. In addition, the anti-proliferative action of NO is associated with the inhibition of polyamine formation (e.g., via ornithine decarboxylase inhibition) and the deterioration of other critical pathways, including down regulation of arginase activity, thereby decreasing tumor growth [110]. These pathways and their endogenous control are complex: Some breast cancer cells lines, for example, were shown to have high arginase activity and very low NOS activity [114]. NO derived from macrophages is known to have tumoricidal activity, and polyamines may promote the growth of tumor cells [115]. Therefore, arginase may be playing a role in promoting tumor growth by inhibiting the production of NO. This may represent a significant fact, given morphine's ability to stimulate cNOS-derived NO release, since this action may not be observed in the presence of arginase [116,117].

Morphine-coupled NO production and release has been shown to be neuroprotective via inhibitory effects on the cellular expression of beta secretase-1 (BACE-1), a key protease involved in maturation of beta amyloid protein in the CNS of Alzheimer patients [118]. Furthermore, inhibitors of beta and gamma secretase decrease endothelial cell proliferation, oppose sprouting of microvessel outgrowths, and inhibit formation of capillary structure [119]. In addition, these inhibitors significantly attenuated growth and vascularization of xenotransplanted human glioblastoma and lung adenocarcinoma into nude mice [119]. Thus, it is hypothesized that the two proteases (secretases) play a role in angiogenesis, since they are also highly expressed in the endothelium of neoforming vessels [119]. It appears, hence, that one of the pathways involved in the anti-tumoral potential of morphine may be the NO-dependent modulation of secretase activity, i.e., decreased angiogenesis. Furthermore, an effect of NO on the induction of anti-angiogenic endostatin has been demonstrated – an effect that has been linked to the inhibition of proliferation and migration of endothelial cells, again illustrating the anti-proliferative potential of NO [120,121]. Given this potential and the physiological morphine-NO coupling, it is comprehensible that biomedical strategies are now looked for that will strengthen a role for opiates and/or NO as potential tumoricidal agents.

A crucial feature of cancer progression and metastasis is the disruption of extracellular matrix and the spreading of proliferating cancer cells. Extracellular matrix, however, is remodeled by matrix metalloproteinases (MMP), and therefore, MMP modulation has become a main target of cancer research [122]. Hence, MMP-2 is under the control of NO, and cNOS activity here seems to be controlled by opioids in a non-opioid receptor manner [122]. Yet, morphine attenuates metalloproteinase activity via the NO/cNOS system as it has been shown, for example, in sarcoma cells [122], again pointing towards possible clinical implications, i.e., for the treatment of sarcomas. In fact, morphine, not opioid-peptides, is coupled to constitutive NO release via the μ_3 receptor in endothelial and immunocompetent cells [24,73,87,88]. Expression of this opioid receptor subtype has been found in human specimens of cancer tissue, e.g., non-small-cell lung carcinoma [112], and thus it has been suggested that the anti-cancer effects of morphine are related, in parts, to cNOS-derived NO release coupled to μ_3 activity [112]. However, increased NO production in lung carcinoma may also indicate that cancer cells use endogenous opiates to down regulate the immune response to tumor growth, i.e., deterioration of host tumor defense capacities. Again, one may realize the complexity of

morphine-nitric oxide interactions in cancer, given the fact that excitatory rebound capacities have also been shown for morphine (as described), and additionally, NO can be produced/released via different pathways that partially act antagonistic, i.e., constitutive (cNOS) and inducible NOS (iNOS) [111,123]. We can thus speak of NO as a double-edged sword, possibly explaining some of the contradictory results in cancer research related to NO and morphine regulation, thereby also acknowledging the fact that certain tumors have the ability to neutralize NO tumoricidal actions.

Taken together, NO may be tumoricidal, e.g., by apoptosis induction [124-126]. However, tumor promoting effects of NO have also been described, underlining the contradictory role of NO in cancer regulation [127-129]. Here we offer rebound effects – that occur in morphine-NO coupling (as described) – as a possible explanation [28-30,103,130], and these effects should be taken into account in future research, which is essentially needed in this field.

Detection and functional characterization of a novel opiate-alkaloid selective μ_3 – like receptor subtype in human umbilical cord stem cells

A considerable body of published work has established a temporal profile of endogenous opioid peptide and opioid receptor gene expression in the development of mammalian brain [131-133]. Recently, similar analyses have demonstrated programmed expression of opioid peptide and opioid receptor genes in cultured neural progenitor cells at various stages of differentiation [134,135]. Human multilineage progenitor cells (MLPC) derived from post-partum umbilical cord blood have recently been established as a high resolution model [136-142] for studying biochemical and molecular mechanisms underlying differentiation of multi-potent progenitor cells into clonal cell lines (e.g., adipocytes, osteoblasts, myocytes, vascular endothelial cells, neurons, astrocytes, and oligodendrocytes). Because MLPC are non-transformed, and non-immortalized, their potential for both proliferation and differentiation into phenotypically distinct clonal lines is temporally defined by the complex chemical profile of their respective microenvironments [143]. Previous studies of opioid regulation of hematopoiesis in adult animals from other groups [144-146] have provided initial insights into the potential role of opioid processes in MLPC maturation.

In a recent study from our laboratory it was demonstrated that a μ_3 -like opiate receptor subtype on MLPC is present [147] (Figure 2). The functional role and potential biological importance of expressed μ_3 opiate receptors are supported by independent lines of pharmacological evidence demonstrating that morphine-evoked release of NO from MLPC is inhibited either by a selective receptor antagonist or by NG-Nitro-L-arginine methyl ester hydrochloride (L-NAME), a competitive inhibitor of cNOS. Importantly, a saturating concentration of the prototype opioid peptide methionine enkephalin, capable of activating traditional μ_1 , delta and kappa opioid receptors, was observed to be without effect on evoked release of NO from human MLPC.

Complementary microarray analysis of extracted RNA indicated that traditional μ_1 , delta, and kappa opioid receptor gene expression is not detected in both undifferentiated and differentiated MLPC, and other prominent classes of neural receptors such as the tachykinin and 5-HT_{2B} are only weakly expressed following differentiation [147]. Incomplete expression of an active DA system is also indicated by the lack of expression of DA₁ and DA₃ receptors and the vesicular DA transporter [147]. The strong expression of the cellular DA transporter suggests that peripherally synthesized DA may taken up and utilized for non-synaptic functions or for the synthesis of endogenous morphine [3,4]. Importantly, candidate genes involved in endogenous morphine biosynthesis including catechol-O-methyl transferase (COMT), CYP2D6, and phenylethanolamine N-methyltransferase (PNMT) are expressed in both undifferentiated and differentiated MLPC, suggesting that MLPC have the potential for

morphine expression. This data also suggests that morphinergic signaling preceded that of catecholamines [148]. Taken together, for the first time, we show elements of an endogenous morphine signaling in progenitor stem cells, suggesting the presence and physiological significance of a μ_3 -receptor during early development.

Functional expression of a μ_3 -like opiate receptor by embryonic stem cells strongly indicates its role as a primordial or progenitor opiate signaling system that has adaptively conserved through evolution. Morphine-mediated NO production may therefore represent the original transductive pathway underlying the cellular actions of opioids. Nitric oxide signaling has been demonstrated in embryonic cells, adding and supporting the current findings [149,150]. NO inhibits Subventricular Zone-derived neural stem cells proliferation, which was found not to involve Cyclic Guanosine Monophosphate (cGMP) synthesis [151]. These neurosphere cells expressed the neuronal and endothelial isoforms of NO and produced NO in culture. This study further suggests NO was acting in an autocrine/paracrine manner. Recent studies demonstrate that NO-cGMP signaling system exists in embryonic stem cells and may be involved in forming committed precursor cells [150]. Our laboratory has hypothesized that basal/tonal NO serves to limit microenvironmental noise, maintain cells in a state in inhibition, thus subserving essential processes of cellular preservation in states of biological readiness [9], and demonstrating the role of NO signaling components in differentiation events or physiological processes of human embryonic stem cells.

In sum, we have identified for the first time in human MLPC the expression of the μ_3 opiate receptor variant of the opiate receptor gene family. These progenitor cells not only expressed this gene, but also the protein produced from this transcript exhibits the biochemical characteristic of the μ_3 receptor by the production of NO in the presence of morphine. This finding is important in further understanding the role of endogenous opiates and opiate receptors in the developmental process, which may have a strong implication in the development of tolerance in pain and in drug addiction. Our data also provide compelling evidence in support of both the evolutionary primacy and primordial regulatory role of a μ_3 -like opiate receptor/NO in embryogenesis.

Working Hypotheses and Conclusions

Tumor progression involves disregulated cellular growth despite controlled release of inhibitory chemical mediators within the micro-environment and normal expression of transcriptional inhibitors. Thus, unconstrained proliferation may represent primitive cellular phenomena whereby regulation via chemical messengers is suspended or compromised or even in a cellular state of developmental aberrations associated with metabolic or transcriptional perturbations of cell cycle. This has been recently suggested by the finding of novel opiate-alkaloid selective receptor subtype in human MLPC [147], which has previously been identified and cloned from various animal tissues, including human, namely the μ_3 receptor [24]. Adding to the significance of morphinergic signaling are the findings of its presence in plant, invertebrate and vertebrate cells, which also have been shown to synthesize this messenger as well [8]. Interestingly, we and others have shown that some human cancerous tissue contain morphine [152-154]. Furthermore, in medullary histolytic reticulosis, which is exemplified by cells having hyperactivity, an absence of μ_3 receptors, suggests a perturbation of morphine-regulated cellular events [155]. Thus, it would appear that morphinergic signaling has inserted itself in many processes taking a long time to evolve during evolution [148], including those regulating the proliferation of cells across diverse phyla.

Morphine may decrease the incidence, development or spread of certain cancers, because it has been associated with down regulation of developmental processes and cell activity, including tumor cells, i.e., tumor growth retardation. Moreover, endogenously expressed

morphine has been demonstrated to initiate a regulatory signaling cascade with anti-proliferative, apoptotic and anti-neoplastic properties, involving protective cNOS-dependent cellular pathways. Opiate alkaloids may have a profound effect on an animal's maturation processes via pharmacological actions at physiologically damaging concentrations, thereby exerting profound perturbation of essential processes mediated by endogenous morphine/NO-coupled signaling [147]. Importantly, mammalian and human cells have the ability to make morphine via a multienzyme mediated process, containing numerous feedback inhibitory steps [3,4], and pharmacological administration of high concentrations of exogenous morphine may one or all of these regulatory steps. Finally, cocaine, alcohol and nicotine may also alter endogenous morphine processes, which now may effect negative consequences on both embryonic and adult stem cell viability and differentiation [156-158].

Acknowledgements

This work was supported in part by Grants DA 09010, MH 47292 and the New York State Empire Innovation Award Program.

References

1. Merlin, MD. On The Trail of Ancient Opium Poppy. London: Associated University Press; 1984.
2. Stefano GB, Fricchione GL, Goumon Y, Esch T. Pain, immunity, opiate and opioid compounds and health. Medical Science Monitor 2005;11:MS47-MS53. [PubMed: 15874900]
3. Zhu W, Mantione KJ, Shen L, Cadet P, Esch T, Goumon Y, et al. Tyrosine and tyramine increase endogenous ganglionic morphine and dopamine levels *in vitro* and *in vivo*: CYP2D6 and tyrosine hydroxylase modulation demonstrates a dopamine coupling. Medical Science Monitor 2005;11:BR397-BR404. [PubMed: 16258388]
4. Zhu W, Cadet P, Baggerman G, Mantione KJ, Stefano GB. Human white blood cells synthesize morphine: CYP2D6 modulation. Journal of Immunology 2005;175:7357-62.
5. Olsen P, Rasmussen M, Stefano GB, Tonnesen EK. Morphine affects the proliferation of tumour cells. Ugeskr Laeger 2004;166:4347-50. [PubMed: 15587623]
6. Olsen P, Rasmussen M, Zhu W, Tonnesen E, Stefano GB. Human gliomas contain morphine. Medical Science Monitor 2005;11:MS18-MS21. [PubMed: 15874895]
7. Cadet P, Rasmussen M, Zhu W, Tonnesen E, Mantione KJ, Stefano GB. Endogenous morphinergic signaling and tumor growth. Frontiers in Bioscience 2004;9:3176-86. [PubMed: 15353348]
8. Kream RM, Stefano GB. De novo biosynthesis of morphine in animal cells: An evidence-based model. Medical Science Monitor 2006;12:RA207-RA219. [PubMed: 17006413]
9. Stefano GB, Goumon Y, Bilfinger TV, Welters I, Cadet P. Basal nitric oxide limits immune, nervous and cardiovascular excitation: Human endothelia express a mu opiate receptor. Progress in Neurobiology 2000;60:513-30. [PubMed: 10739087]
10. Stefano GB, Goumon Y, Casares F, Cadet P, Fricchione GL, Rialas C, et al. Endogenous morphine. Trends in Neurosciences 2000;9:436-42. [PubMed: 10941194]
11. El Mouedden M, Meert TF. The impact of the opioids fentanyl and morphine on nociception and bone destruction in a murine model of bone cancer pain. Pharmacol Biochem Behav 2007;87:30-40. [PubMed: 17521715]
12. Page GG, Ben Eliyahu S, Yirmiya R, Liebeskind JC. Morphine attenuates surgery-induced enhancement of metastatic colonization in rats. Pain 1993;54:21-8. [PubMed: 8378099]
13. Page GG, Ben Eliyahu S, Liebeskind JC. The role of LGL/NK cells in surgery-induced promotion of metastasis and its attenuation by morphine. Brain Behav Immun 1994;8:241-50. [PubMed: 7865895]
14. Page GG, McDonald JS, Ben Eliyahu S. Pre-operative versus postoperative administration of morphine: impact on the neuroendocrine, behavioural, and metastatic-enhancing effects of surgery. Br J Anaesth 1998;81:216-23. [PubMed: 9813526]
15. Yeager MP, Colacchio TA. Effect of morphine on growth of metastatic colon cancer in vivo. Arch Surg 1991;126:454-6. [PubMed: 2009060]

16. Hatzoglou A, Bakogeorgou E, Castanas E. The antiproliferative effect of opioid receptor agonists on the T47D human breast cancer cell line, is partially mediated through opioid receptors. *Eur J Pharmacol* 1996;296:199–207. [PubMed: 8838457]
17. Zagon IS, McLaughlin PJ, Goodman SR, Rhodes RE. Opioid receptors and endogenous opioids in diverse human and animal cancers. *J Natl Cancer Inst* 1987;79:1059–65. [PubMed: 2824913]
18. Maneckjee R, Minna JD. Opioid and nicotine receptors affect growth regulation of human lung cancer cell lines. *Proc Natl Acad Sci, USA* 1990;87:3294–8. [PubMed: 2159143]
19. Hatzoglou A, Ouafik L, Bakogeorgou E, Thermos K, Castanas E. Morphine cross-reacts with somatostatin receptor SSTR2 in the T47D human breast cancer cell line and decreases cell growth. *Cancer Res* 1995;55:5632–6. [PubMed: 7585646]
20. Bogden AE, Taylor JE, Moreau JP, Coy DH, LePage DJ. Response of human lung tumor xenografts to treatment with a somatostatin analogue (Somatuline). *Cancer Res* 1990;50:4360–5. [PubMed: 1973071]
21. Prevost G, Foehrle E, Thomas F, Pihan I, Veber N, Starzec A, et al. Growth of human breast cancer cell lines is inhibited by the somatostatin analog BIM23014. *Endocrinology* 1991;129:323–9. [PubMed: 2055192]
22. Setyono-Han B, Henkelman MS, Foekens JA, Klijn GM. Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells. *Cancer Res* 1987;47:1566–70. [PubMed: 2880660]
23. Cadet P, Bilfinger TV, Fimiani C, Peter D, Stefano GB. Human vascular and cardiac endothelia express mu opiate receptor transcripts. *Endothelium* 2000;7:185–91. [PubMed: 10912912]
24. Cadet P, Mantione KJ, Stefano GB. Molecular identification and functional expression of mu3, a novel alternatively spliced variant of the human mu opiate receptor gene. *Journal of Immunology* 2003;170:5118–23.
25. Gupta K, Kshirsagar S, Chang L, Schwartz R, Law PY, Yee D, et al. Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. *Cancer Res* 2002;62:4491–8. [PubMed: 12154060]
26. Singleton PA, Lingen MW, Fekete MJ, Garcia JG, Moss J. Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: role of receptor transactivation. *Microvasc Res* 2006;72:3–11. [PubMed: 16820176]
27. Stefano GB, Scharrer B. Endogenous morphine and related opiates, a new class of chemical messengers. *Adv Neuroimmunol* 1994;4:57–68. [PubMed: 7952829]
28. Stefano GB. Autoimmunovascular regulation: Morphine and anandamide stimulated nitric oxide release. *Journal of Neuroimmunology* 1998;83:70–6. [PubMed: 9610675]
29. Stefano GB, Leung MK, Bilfinger TV, Scharrer B. Effect of prolonged exposure to morphine on responsiveness of human and invertebrate immunocytes to stimulatory molecules. *J Neuroimmunol* 1995;63:175–81. [PubMed: 8550815]
30. Magazine HI, Chang J, Goumon Y, Stefano GB. Rebound from nitric oxide inhibition triggers enhanced monocyte activation and chemotaxis. *J Immunol* 2000;165:102–7. [PubMed: 10861041]
31. Provinciali M, Di Stefano G, Raffaelli W, Pari G, Desiderio F, Fabris N. Evaluation of NK and LAK cell activities in neoplastic patients during treatment with morphine. *Int J Neurosci* 1991;59:127–33. [PubMed: 1774133]
32. Fuggetta MP, Di FP, Falchetti R, Cottarelli A, Rossi L, Tricarico M, et al. Effect of morphine on cell-mediated immune responses of human lymphocytes against allogeneic malignant cells. *J Exp Clin Cancer Res* 2005;24:255–63. [PubMed: 16110759]
33. Shavit Y, Ben-Eliyahu S, Zeidel A, Beilin B. Effects of fentanyl on natural killer cell activity and on resistance to tumor metastasis in rats. Dose and timing study. *Neuroimmunomodulation* 2004;11:255–60. [PubMed: 15249732]
34. Stefano GB, Scharrer B, Smith EM, Hughes TK, Magazine HI, Bilfinger TV, et al. Opioid and opiate immunoregulatory processes. *Crit Rev in Immunol* 1996;16:109–44. [PubMed: 8879941]
35. Stefano GB, Salzet B, Fricchione GL. Enkelytin and opioid peptide association in invertebrates and vertebrates: Immune activation and pain. *Immunol Today* 1998;19:265–8. [PubMed: 9639991]

36. Payabvash S, Beheshtian A, Salmasi AH, Kiumehr S, Ghahremani MH, Tavangar SM, et al. Chronic morphine treatment induces oxidant and apoptotic damage in the mice liver. *Life Sci* 2006;79:972–80. [PubMed: 16750225]
37. Maneckjee R, Minna JD. Opioids induce while nicotine suppresses apoptosis in human lung cancer cells. *Cell Growth Differ* 1994;5:1033–40. [PubMed: 7848904]
38. Sueoka N, Sueoka E, Okabe S, Fujiki H. Anti-cancer effects of morphine through inhibition of tumour necrosis factor- α release and mRNA expression. *Carcinogenesis* 1996;17:2337–41. [PubMed: 8968046]
39. Shakhov AN, Collart MA, Vassalli P, Nedospasov SA, Jongeneel CV. Kappa B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor alpha gene in primary macrophages. *J Exp Med* 1990;171:35–47. [PubMed: 2104921]
40. Esch T, Stefano GB. Proinflammation: A common denominator or initiator of different pathophysiological disease processes. *Medical Science Monitor* 2002;8:1–9.
41. Sueoka E, Sueoka N, Kai Y, Suganuma M, Kanematsu K, Yamamoto T, et al. Anticancer activity of morphine and its synthetic derivative, KT-90, mediated through apoptosis and inhibition of NF- κ B activation. *Biochem Biophys Res Commun* 1998;252:566–70. [PubMed: 9837747]
42. Jeremias I, Kupatt C, Baumann B, Herr I, Wirth T, Debatin KM. Inhibition of nuclear factor kappaB activation attenuates apoptosis resistance in lymphoid cells. *Blood* 1998;91:4624–31. [PubMed: 9616159]
43. Welters ID, Fimiani C, Bilfinger TV, Stefano GB. NF- κ B, nitric oxide and opiate signaling. *Medical Hypotheses* 1999;54:263–8. [PubMed: 10790762]
44. Welters ID, Menzebach A, Goumon Y, Cadet P, Menges T, Hughes TK, et al. Morphine inhibits NF- κ B nuclear binding in human neutrophils and monocytes by a nitric oxide dependent mechanism. *Anesthesiol* 2000;92:1677–84.
45. Lord JAH, Waterfield AA, Hughes J, Kosterlitz HW. Endogenous opioid peptides: Multiple agonists and receptors. *Nature* 1977;267:495–9. [PubMed: 195217]
46. Gintzler AR, Levy A, Spector S. Antibodies as a means of isolating and characterizing biologically active substances: Presence of a non-peptide morphine-like compound in the central nervous system. *Proc Natl Acad Sci USA* 1976;73:2132–6. [PubMed: 1064881]
47. Gintzler AR, Gershon MD, Spector S. A nonpeptide morphine-like compound: immunocytochemical localization in the mouse brain. *Science* 1978;199:447–8. [PubMed: 339350]
48. Stefano GB, Digenis A, Spector S, Leung MK, Bilfinger TV, Makman MH, et al. Opiate-like substances in an invertebrate, an opiate receptor on invertebrate and human immunocytes, and a role in immunosuppression. *Proc Natl Acad Sci USA* 1993;90:11099–103. [PubMed: 8248214]
49. Zhu W, Mantione KJ, Shen L, Stefano GB. In vivo and in vitro L-DOPA exposure increases ganglionic morphine levels. *Medical Science Monitor* 2005;11:MS1–MS5. [PubMed: 15874894]
50. Poeaknapo C, Schmidt J, Brandsch M, Drager B, Zenk MH. Endogenous formation of morphine in human cells. *Proc Natl Acad Sci U S A* 2004;101:14091–6. [PubMed: 15383669]
51. Boettcher C, Fellermeier M, Boettcher C, Drager B, Zenk MH. How human neuroblastoma cells make morphine. *Proc Natl Acad Sci U S A* 2005;102:8495–500. [PubMed: 15937106]
52. Hiroi T, Imaoka S, Funae Y. Dopamine formation from tyramine by CYP2D6. *Biochem Biophys Res Commun* 1998;249:838–43. [PubMed: 9731223]
53. Miller GP, Hanna IH, Nishimura Y, Guengerich FP. Oxidation of phenethylamine derivatives by cytochrome P450 2D6: the issue of substrate protonation in binding and catalysis. *Biochemistry* 2001;40:14215–23. [PubMed: 11714275]
54. Guengerich FP, Miller GP, Hanna IH, Sato H, Martin MV. Oxidation of methoxyphenethylamines by cytochrome P450 2D6. Analysis of rate-limiting steps. *J Biol Chem* 2002;277:33711–9. [PubMed: 12093814]
55. Niwa T, Hiroi T, Tsuzuki D, Yamamoto S, Narimatsu S, Fukuda T, et al. Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. *Brain Res Mol Brain Res* 2004;129:117–23. [PubMed: 15469888]
56. Esch T, Guarna M, Bianchi E, Zhu W, Stefano GB. Commonalities in the central nervous system's involvement with complementary medical therapies: Limbic morphinergic processes. *Medical Science Monitor* 2004;10:MS6–MS17. [PubMed: 15173679]

57. Stefano GB, Zhu W, Cadet P, Mantione K. Morphine enhances nitric oxide release in the mammalian gastrointestinal tract via the μ_3 opiate receptor subtype: A hormonal role for endogenous morphine. *Journal of Physiology and Pharmacology* 2004;55:279–88. [PubMed: 15082884]
58. Donnerer J, Oka K, Brossi A, Rice KC, Spector S. Presence and formation of codeine and morphine in the rat. *Proc Natl Acad Sci USA* 1986;83:4566–7. [PubMed: 3459191]
59. Lee SC, Spector S. DON'T USE Changes in Endogenous Morphine and Codeine contents in the fasting rat. *Journal of Pharmacology & Experimental Therapeutics* 1991;257:647–52. [PubMed: 2033511]
60. Epple A, Nibbio B, Spector S, Brinn J. Endogenous codeine: autocrine regulator of catecholamine release from chromaffin cells. *Life Sci* 1994;54:695–702. [PubMed: 8107518]
61. Zhu W, Ma Y, Cadet P, Yu D, Bilfinger TV, Bianchi E, et al. Presence of reticuline in rat brain: A pathway for morphine biosynthesis. *Mol Brain Res* 2003;117:83–90.
62. Goumon Y, Casares F, Zhu W, Stefano GB. The presence of morphine in ganglionic tissues of *Modiolus deminissus*: A highly sensitive method of quantitation for morphine and its derivatives. *Mol Brain Res* 2001;86:184–8.
63. Zhu W, Baggerman G, Goumon Y, Casares F, Brownawell B, Stefano GB. Presence of morphine and morphine-6-glucuronide in the marine mollusk *Mytilus edulis* ganglia determined by GC/MS and Q-TOF-MS. Starvation increases opiate alkaloid levels. *Brain Res Mol Brain Res* 2001;88:155–60. [PubMed: 11295241]
64. Zhu W, Ma Y, Stefano GB. Presence of isoquinoline alkaloids in molluscan ganglia. *Neuroendocrinol Lett* 2002;23:329–34. [PubMed: 12195236]
65. Brix-Christensen V, Tonnesen E, Sanchez RG, Bilfinger TV, Stefano GB. Endogenous morphine levels increase following cardiac surgery as part of the antiinflammatory response? *Int J Cardiol* 1997;62:191–7. [PubMed: 9476677]
66. Cadet P, Zhu W, Mantione K, Rymer M, Dardik I, Reisman S, et al. Cyclic exercise induces anti-inflammatory signal molecule increases in the plasma of Parkinson's patients. *Int J Mol Med* 2003;12:485–92. [PubMed: 12964024]
67. Stefano GB, Zhu W, Cadet P, Mantione K, Bilfinger TV, Bianchi E, et al. A hormonal role for endogenous opiate alkaloids: Vascular tissues. *Neuroendocrinology Letters* 2002;23:21–6. [PubMed: 11880858]
68. Pasternak, GW. *The Opiate Receptors*. New Jersey: Humana Press; 1988.
69. Makman MH, Bilfinger TV, Stefano GB. Human granulocytes contain an opiate receptor mediating inhibition of cytokine-induced activation and chemotaxis. *J Immunol* 1995;154:1323–30. [PubMed: 7822801]
70. Stefano GB. The μ_3 opiate receptor subtype. *Pain Forum* 1999;8:206–9.
71. Cruciani RA, Dvorkin B, Klinger HP, Makman MH. Presence in neuroblastoma cells of a μ_3 receptor with selectivity for opiate alkaloids but without affinity for opioid peptides. *Brain Res* 1994;667:229–37. [PubMed: 7697360]
72. Makman MH, Dvorkin B, Stefano GB. Murine macrophage cell lines contain μ_3 -opiate receptors. *Eur J Pharmacol* 1995;273:R5–R6. [PubMed: 7737324]
73. Stefano GB, Hartman A, Bilfinger TV, Magazine HI, Liu Y, Casares F, et al. Presence of the μ_3 opiate receptor in endothelial cells: Coupling to nitric oxide production and vasodilation. *J Biol Chem* 1995;270:30290–3. [PubMed: 8530450]
74. Dobrenis K, Makman MH, Stefano GB. Occurrence of the opiate alkaloid-selective μ_3 receptor in mammalian microglia, astrocytes and kupffer cells. *Brain Res* 1995;686:239–48. [PubMed: 7583289]
75. Stefano GB, Scharrer B. The presence of the μ_3 opiate receptor in invertebrate neural tissues. *Comp Biochem Physiol* 1996;113C:369–73.
76. Rialas C, Bilfinger TV, Salzet M, Stefano GB. Endomorphin 1 and 2 do not interact with the μ_3 opiate receptor subtype. *Acta Pharmacol Sin* 1998;19:403–7.
77. Pasternak GW. Multiple μ opiate receptors: Biochemical and pharmacological evidence for multiplicity. *Biochem Pharmacol* 1986;35:361–4. [PubMed: 3004499]
78. Clark JA, Liu L, Price M, Hersh BS, Edelson M, Pasternak GW. Kappa opiate receptor multiplicity: Evidence for two U50, 488- sensitive K1 subtypes and a novel K3 subtype. *J Pharmacol Exp Ther* 1989;251:461–8. [PubMed: 2553920]

79. Rothman RB, Bykov V, DeCosta BR, Jacobson AE, Rice KC, Brady LS. Interaction of endogenous opioid peptides and other drugs with four kappa binding sites in guinea pig brain. *Peptides* 1990;11:311–31. [PubMed: 2162533]
80. Mattia A, Farmer SC, Takemori AE, Sultana M, Portoghesi PS, Mosberg HI, et al. Spinal opioid *delta* antinociception in the mouse mediation by a 5'-NTII-sensitive *delta* receptor subtype. *J Pharmacol Exp Ther* 1992;260:518–25. [PubMed: 1310737]
81. Stefano GB, Melchiorri P, Negri L, Hughes TK, Scharer B. (D-Ala2)-Deltorphin I binding and pharmacological evidence for a special subtype of delta opioid receptor on human and invertebrate immune cells. *Proc Natl Acad Sci USA* 1992;89:9316–20. [PubMed: 1329092]
82. Traynor JR, Elliott J. δ -Opioid receptor subtypes and cross-talk with mu-receptors. *Trends Pharmacol Sci* 1993;14:84–6. [PubMed: 8387705]
83. Kieffer BL, Befort K, Gaveriaux-Ruff CE, Hirth CG. The δ -opioid receptor: Isolation of a cDNA by expression cloning and pharmacological characterization. *Proc Natl Acad Sci, USA* 1992;89:12048–52. [PubMed: 1334555]
84. Evans CJ, Keith DE Jr, Morrison H, Magendzo K, Edwards RH. Cloning of a delta opioid receptor by functional expression. *Science* 1992;258:1952–5. [PubMed: 1335167]
85. Chen Y, Mestek A, Liu J, Hurley JA, Yu L. Molecular cloning and functional expression of a μ -opioid receptor from rat brain. *Mol Pharmacol* 1993;44:8–12. [PubMed: 8393525]
86. Yasuda K, Raynor K, Kong H, Breder CD, Takeda J, Reisine T, et al. Cloning and functional comparison of κ and δ -opioid receptors from mouse brain. *Proc Natl Acad Sci, USA* 1993;90:6736–40. [PubMed: 8393575]
87. Stefano GB, Hartman A, Bilfinger TV, Magazine HI, Liu Y, Casares F, et al. Presence of the μ 3 opiate receptor in endothelial cells. Coupling to nitric oxide production and vasodilation. *Journal of Biological Chemistry* 1995;270:30290–3. [PubMed: 8530450]
88. Magazine HI, Liu Y, Bilfinger TV, Fricchione GL, Stefano GB. Morphine-induced conformational changes in human monocytes, granulocytes, and endothelial cells and in invertebrate immunocytes and microglia are mediated by nitric oxide. *J Immunol* 1996;156:4845–50. [PubMed: 8648133]
89. Liu Y, Shenouda D, Bilfinger TV, Stefano ML, Magazine HI, Stefano GB. Morphine stimulates nitric oxide release from invertebrate microglia. *Brain Res* 1996;722:125–31. [PubMed: 8813357]
90. Sonetti D, Ottaviani E, Stefano GB. Opiate signaling regulates microglia activities in the invertebrate nervous system. *Gen Pharmacol* 1997;29:39–47. [PubMed: 9195191]
91. Matthes HWD, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the μ opioid receptor gene. *Nature* 1996;383:819–23. [PubMed: 8893006]
92. Cadet P, Stefano GB. *Mytilus edulis* pedal ganglia express μ opiate receptor transcripts exhibiting high sequence identity with human neuronal μ 1. *Mol Brain Res* 1999;74:242–6.
93. Ferreira SH, Duarte ID, Lorenzetti BB. The molecular mechanism of action of peripheral morphine analgesia: Stimulation of the cGMP system via nitric oxide release. *Eur J Pharmacol* 1991;201:121. [PubMed: 1665419]
94. Przewlocki R, Machelska H, Przewlocka B. Inhibition of nitric oxide synthase enhances morphine antinociception in the rat spinal cord. *Life Sci* 1993;53:PL1–5. [PubMed: 7685846]
95. Majeed NH, Przewlocka B, Machelska H, Przewlocki R. Inhibition of nitric oxide synthase attenuates the development of morphine tolerance and dependence in mice. *Neuropharmacology* 1994;33:189–92. [PubMed: 7518573]
96. Fecho K, Maslonek KA, Coussons-Read ME, Dykstra LA, Lysle DT. Macrophage-derived nitric oxide is involved in the depressed concanavalin A responsiveness of splenic lymphocytes from rats administered morphine in vivo. *J Immunol* 1994;152:5845–51. [PubMed: 8207211]
97. Gyires K. The role of endogenous nitric oxide in the gastroprotective action of morphine. *Eur J Pharmacol* 1994;255:33–7. [PubMed: 8026553]
98. Bilfinger TV, Hartman A, Liu Y, Magazine HI, Stefano GB. Cryopreserved veins used for myocardial revascularization: A 5 year experience and a possible mechanism for their increased failure. *Ann Thorac Surg* 1997;63:1063–9. [PubMed: 9124906]
99. Sawada M, Ichinose M, Stefano GB. Nitric oxide inhibits the dopamine-induced K^+ current via guanylate cyclase in *Aplysia* neurons. *J Neurosci Res* 1997;50:450–6. [PubMed: 9364330]

100. Stefano GB, Salzet B, Rialas CM, Pope M, Kustka A, Neenan K, et al. Morphine and anandamide stimulated nitric oxide production inhibits presynaptic dopamine release. *Brain Res* 1997;763:63–8. [PubMed: 9272829]
101. Bilfinger TV, Fimiani C, Stefano GB. Morphine's immunoregulatory actions are not shared by fentanyl. *Int J Cardiol* 1998;64:61–6.
102. Prevot V, Rialas C, Croix D, Salzet M, Dupouy JP, Puolain P, et al. Morphine and anandamide coupling to nitric oxide stimulated GnRH and CRF release from rat median eminence: Neurovascular regulation. *Brain Res* 1998;790:236–44. [PubMed: 9593913]
103. Stefano GB, Salzet M, Bilfinger TV. Long-term exposure of human blood vessels to HIV gp120, morphine and anandamide increases endothelial adhesion of monocytes: Uncoupling of Nitric Oxide. *J Cardiovasc Pharmacol* 1998;31:862–8. [PubMed: 9641470]
104. Stefano GB, Salzet M, Magazine HI, Bilfinger TV. Antagonist of LPS and IFN- γ induction of iNOS in human saphenous vein endothelium by morphine and anandamide by nitric oxide inhibition of adenylate cyclase. *J Cardiovasc Pharmacol* 1998;31:813–20. [PubMed: 9641464]
105. Rasmussen M, Zhu W, Tonnesen J, Cadet P, Tonnesen E, Stefano GB. Effects of morphine on tumour growth. *Neuroendocrinology Letters* 2002;23:193–8. [PubMed: 12080278]
106. Tubaro E, Borelli G, Croce C, Cavallo G, Santiangeli C. Effect of morphine on resistance to infection. *J Infect Dis* 1983;148:656–66. [PubMed: 6355311]
107. Weber RJ, Band LC, DeCosta B, Pert A, Rice KC. Neural control of immune function: Opioids, opioid receptors and immunosuppression. *NIDA Res Monogr* 1991;105:96–102. [PubMed: 1652096]
108. Perez-Castrillon JP, Perez-Arellano JP, Garcia-Palomo JD, Jimenez-Lopez A, DeCastro S. Opioids depress in vitro human monocyte chemotaxis. *Immunopharmacol* 1992;23:57–61.
109. Stefano GB, Bilfinger TV. Human neutrophil and macrophage chemokinesis induced by cardiopulmonary bypass: Loss of DAME and IL-1 chemotaxis. *J Neuroimmunol* 1993;47:189–98. [PubMed: 8370770]
110. Buga GM, Wei LH, Bauer PM, Fukuto JM, Ignarro LJ. NG-hydroxy-L-arginine and nitric oxide inhibit Caco-2 tumor cell proliferation by distinct mechanisms. *Am J Physiol* 1998;275:R1256–R1264. [PubMed: 9756558]
111. Esch T, Stefano GB, Fricchione GL, Benson H. Stress-related diseases: A potential role for nitric oxide. *Medical Science Monitor* 2002;8:RA103–RA118. [PubMed: 12070451]
112. Fimiani C, Arcuri E, Santoni A, Rialas C, Bilfinger TV, Peter D, et al. Mu₃ opiate receptor expression in lung ang lung carcinoma: Ligand binding and coupling to nitric oxide release. *Cancer Letters* 1999;146:45–51. [PubMed: 10656608]
113. Welters ID, Menzebach A, Goumon Y, Langefeld TW, Teschemacher H, Hempelmann G, et al. Morphine suppresses complement receptor expression, phagocytosis, and respiratory burst in neutrophils by a nitric oxide and mu(3) opiate receptor-dependent mechanism. *J Neuroimmunol* 2000;111:139–45. [PubMed: 11063831]
114. Singh R, Pervin S, Karimi A, Cederbaum S, Chaudhuri G. Arginase activity in human breast cancer cell lines: N(omega)-hydroxy-L-arginine selectively inhibits cell proliferation and induces apoptosis in MDA-MB-468 cells. *Cancer Res* 2000;60:3305–12. [PubMed: 10866325]
115. Chang CI, Liao JC, Kuo L. Macrophage arginase promotes tumor cell growth and suppresses nitric oxide-mediated tumor cytotoxicity. *Cancer Res* 2001;61:1100–6. [PubMed: 11221839]
116. Mantione KJ, Cadet P, Zhu W, Kream RM, Sheehan M, Fricchione GL, et al. Endogenous morphine signaling via nitric oxide regulates the expression of CYP2D6 and COMT: autocrine/paracrine feedback inhibition. *Addict Biol.* in press
117. Zhu W, Ma Y, Bell A, Esch T, Guarna M, Bilfinger TV, et al. Presence of morphine in rat amygdala: Evidence for the mu₃ opiate receptor subtype via nitric oxide release in limbic structures. *Med Sci Monit* 2004;10:BR433–BR439. [PubMed: 15567973]
118. Pak T, Cadet P, Mantione KJ, Stefano GB. Morphine via nitric oxide modulates beta-amyloid metabolism: a novel protective mechanism for Alzheimer's disease. *Med Sci Monit* 2005;11:BR357–BR366. [PubMed: 16192893]

119. Paris D, Quadros A, Patel N, DelleDonne A, Humphrey J, Mullan M. Inhibition of angiogenesis and tumor growth by beta and gamma-secretase inhibitors. *Eur J Pharmacol* 2005;514:1–15. [PubMed: 15878319]
120. Jiang L, Jha V, Dhanabal M, Sukhatme VP, Alper SL. Intracellular Ca(2+) signaling in endothelial cells by the angiogenesis inhibitors endostatin and angiostatin. *Am J Physiol Cell Physiol* 2001;280:C1140–C1150. [PubMed: 11287327]
121. Deininger MH, Wybranietz WA, Graepler FT, Lauer UM, Meyermann R, Schluesener HJ. Endothelial endostatin release is induced by general cell stress and modulated by the nitric oxide/cGMP pathway. *FASEB J* 2003;17:1267–76. [PubMed: 12832291]
122. Sharifabrizi A, Nifli AP, Ansari M, Saadat F, Ebrahimkhani MR, Alizadeh N, et al. Matrix metalloproteinase 2 secretion in WEHI 164 fibrosarcoma cells is nitric oxide-related and modified by morphine. *Eur J Pharmacol* 2006;530:33–9. [PubMed: 16386243]
123. Gobert AP, McGee DJ, Akhtar M, Mendz GL, Newton JC, Cheng Y, et al. *Helicobacter pylori* arginase inhibits nitric oxide production by eukaryotic cells: a strategy for bacterial survival. *Proc Natl Acad Sci U S A* 2001;98:13844–9. [PubMed: 11717441]
124. Nicotera P, Bonfoco E, Brune B. Mechanisms for nitric oxide-induced cell death: involvement of apoptosis. *Adv Neuroimmunol* 1995;5:411–20. [PubMed: 8746513]
125. Xie K, Huang S, Dong Z, Gutman M, Fidler IJ. Direct correlation between expression of endogenous inducible nitric oxide synthase and regression of M5076 reticulum cell sarcoma hepatic metastases in mice treated with liposomes containing lipopeptide CGP 31362. *Cancer Res* 1995;55:3123–31. [PubMed: 7541713]
126. Xie K, Huang S, Dong Z, Juang SH, Gutman M, Xie QW, et al. Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells. *J Exp Med* 1995;181:1333–43. [PubMed: 7535333]
127. Lejeune P, Lagadec P, Onier N, Pinard D, Ohshima H, Jeannin JF. Nitric oxide involvement in tumor-induced immunosuppression. *J Immunol* 1994;152:5077–83. [PubMed: 7513729]
128. Wink DA, Vodovotz Y, Laval J, Laval F, Dewhirst MW, Mitchell JB. The multifaceted roles of nitric oxide in cancer. *Carcinogenesis* 1998;19:711–21. [PubMed: 9635855]
129. Kampa M, Hatzoglou A, Notas G, Niniraki M, Kouroumalis E, Castanas E. Opioids are non-competitive inhibitors of nitric oxide synthase in T47D human breast cancer cells. *Cell Death Differ* 2001;8:943–52. [PubMed: 11526449]
130. Stefano GB, Salzet M, Rialas C, Mattocks DW, Fimiani C, Bilfinger TV. Macrophage behavior associated with acute and chronic exposure to HIV GP120, morphine and anandamide: Endothelial implications. *Int J Cardiol* 1998;64:S3–S13. [PubMed: 9687087]
131. Zamir N, Quirion R, Segal M. Ontogeny and regional distribution of proenkephalin- and prodynorphin-derived peptides and opioid receptors in rat hippocampus. *Neuroscience* 1985;15:1025–34. [PubMed: 2995868]
132. Leslie FM, Chen Y, Winzer-Serhan UH. Opioid receptor and peptide mRNA expression in proliferative zones of fetal rat central nervous system. *Can J Physiol Pharmacol* 1998;76:284–93. [PubMed: 9673792]
133. Zhu Y, Hsu MS, Pinter JE. Developmental expression of the mu, kappa, and delta opioid receptor mRNAs in mouse. *J Neurosci* 1998;18:2538–49. [PubMed: 9502813]
134. Ventura C, Maioli M. Opioid peptide gene expression primes cardiogenesis in embryonal pluripotent stem cells. *Circ Res* 2000;87:189–94. [PubMed: 10926868]
135. Kim E, Clark AL, Kiss A, Hahn JW, Wesselschmidt R, Coscia CJ, et al. Mu- and kappa-opioids induce the differentiation of embryonic stem cells to neural progenitors. *J Biol Chem* 2006;281:33749–60. [PubMed: 16954126]
136. BioE Inc.. Methods for directed differentiation of MLPC. Rev. 2. 2005.
137. Collins, DP. Isolation and Characterization of Umbilical Cord Blood-Derived Multipotent Stem Cells Arising from an Adherent CD45+/CD34+ Cell Subset. 4th Annual International Umbilical Cord Blood Transplantation Symposium; 2006.
138. Forraz, N.; Baradez, MO.; McGuckin, CP. Characterization of the First Umbilical Cord Blood Multi-Lineage Progenitor Cell Line by High-Definition Microarray. 8th Annual Meeting of the International Tissue Engineering Society; 2005.

139. Forraz N, Collins DP, Baradez MO, McGuckin CP. Characterization of the First Human Umbilical Cord Blood Multi-Lineage Progenitor Cell Line. *Tissue Models for Therapeutics*. 2005
140. BioE Inc.. Development of clonal Cell Lines with Multi-Lineage Potential from Human Umbilical Cord Blood, Methods of Isolation, Expansion, and Differentiation. 3rd Annual Meeting of the International Society for Stem Cell Research; 2005.
141. Goodwin HS, Bicknese AR, Chien SN, Bogucki BD, Quinn CO, Wall DA. Multilineage differentiation activity by cells isolated from umbilical cord blood: expression of bone, fat, and neural markers. *Biol Blood Marrow Transplant* 2001;7:581–8. [PubMed: 11760145]
142. Lee OK, Kuo TK, Chen WM, Lee KD, Hsieh SL, Chen TH. Isolation of multipotent mesenchymal stem cells from umbilical cord blood. *Blood* 2004;103:1669–75. [PubMed: 14576065]
143. Horowitz D, Callahan JF, Pelus LM, Fukuda S, King AG. Inhibition of hematopoietic progenitor cell growth by Tyr-MIF, an endogenous opiate modulator, and its degradation products. *Int Immunopharmacol* 2002;2:721–30. [PubMed: 12013510]
144. Rameshwar P, Poddar A, Gascon P. Hematopoietic regulation mediated by interactions among the neurokinins and cytokines. *Leuk Lymphoma* 1997;28:1–10. [PubMed: 9498698]
145. Broome CS, Whetton AD, Miyan JA. Neuropeptide control of bone marrow neutrophil production is mediated by both direct and indirect effects on CFU-GM. *Br J Haematol* 2000;108:140–50. [PubMed: 10651737]
146. Sharp BM, Roy S, Bidlack JM. Evidence for opioid receptors on cells involved in host defense and the immune system. *J Neuroimmunol* 1998;83:45–56. [PubMed: 9610672]
147. Cadet P, Mantione KJ, Zhu W, Kream RM, Sheehan M, Stefano GB. A functionally coupled mu3-like opiate receptor/nitric oxide regulatory pathway in human multi-lineage progenitor cells. *Journal of Immunology*. in press
148. Stefano GB, Kream RM. Endogenous morphine synthetic pathway preceded and gave rise to catecholamine synthesis in evolution (Review). *Int J Mol Med*. in press
149. Mujoo K, Krumenacker JS, Wada Y, Murad F. Differential expression of nitric oxide signaling components in undifferentiated and differentiated human embryonic stem cells. *Stem Cells Dev* 2006;15:779–87. [PubMed: 17253941]
150. Madhusoodanan KS, Murad F. NO-cGMP signaling and regenerative medicine involving stem cells. *Neurochem Res* 2007;32:681–94. [PubMed: 17043768]
151. Torroglosa A, Murillo-Carretero M, Romero-Grimaldi C, Matarredona ER, Campos-Caro A, Estrada C. Nitric oxide decreases subventricular zone stem cell proliferation by inhibition of epidermal growth factor receptor and phosphoinositide-3-kinase/Akt pathway. *Stem Cells* 2007;25:88–97. [PubMed: 16960136]
152. Goumon Y, Weeks BS, Cadet P, Stefano GB. Identification of morphine in the adrenal medullary chromaffin PC-12 cell line. *Mol Brain Res* 2000;81:177–80.
153. Zhu W, Baggerman G, Goumon Y, Zenk MH, Stefano GB. Identification of morphine and morphine-6-glucuronide in the adrenal medullary chromaffin PC-12 cell line by nano electrospray ionization double quadrupole orthogonal acceleration time of flight mass spectrometry. *Eur J of Mass Spect* 2001;7:25–8.
154. Poeknapo C, Schmidt J, Brandsch M, Dräger B, Zenk MH. Endogenous formation of morphine in human cells. *Proceedings of the National Academy of Sciences of the USA* 2004;101:14091–6. [PubMed: 15383669]
155. Fricchione GL, Cytryn L, Bilfinger TV, Stefano GB. Cell behavior and signal molecule involvement in a case study of malignant histiocytosis: A negative model of morphine as an immunoregulator. *Am J Hematol* 1997;56:197–205. [PubMed: 9395179]
156. Zhu W, Mantione KJ, Casares FM, Cadet P, Kim JW, Bilfinger TV, et al. Alcohol-, nicotine-, and cocaine-evoked release of morphine from invertebrate ganglia: Model system for screening drugs of abuse. *Medical Science Monitor* 2006;12:BR155–BR161. [PubMed: 16641868]
157. Zhu W, Mantione KJ, Casares FM, Sheehan MH, Kream RM, Stefano GB. Cholinergic regulation of endogenous morphine release from lobster nerve cord. *Med Sci Monit* 2006;12:BR295–BR301. [PubMed: 16940924]
158. Zhu W, Mantione K, Kream RM, Stefano GB. Alcohol-, Nicotine-, and Cocaine-Evoked Release of Morphine from Human White Blood Cells: Substances of Abuse Actions Converge on

Endogenous Morphine Release. Medical Science Monitor 2006;12:BR350–BR354. [PubMed: 17072263]

Figure 1. Detailed schematic indicating relevant enzymes and chemical intermediates in the morphine biosynthetic pathway

Above: A 3-dimensional 26 amino acid sequence representing the unique intracellular domain of the μ_3 receptor

Right: A 3-dimensional 4 amino acid sequence representing the unique intracellular domain of a μ_3 -like receptor

White=H; Grey=C; Blue=N; Red=O;
Yellow=S

Figure 2.